Information  X 
Enter a valid email address

Royal Bk Scot.Grp. (RBS)

  Print      Mail a friend

Wednesday 30 October, 2019

Royal Bk Scot.Grp.

RBSG pricing of US$750mn of Subordinated Notes

RNS Number : 6123R
Royal Bank of Scotland Group PLC
30 October 2019
 

The Royal Bank of Scotland Group plc

 

30 October 2019

 

The Royal Bank of Scotland Group plc ("RBSG") completed the pricing of its $750,000,000 Fixed-to-Fixed Reset Rate Subordinated Notes due 2029.

The proceeds to RBSG (before expenses and underwriting discounts) of $750,000,000 will be used to fund RBSG's general banking business. 

The offering is scheduled to close on 1 November 2019, subject to the satisfaction of customary conditions.

 

RBSG has filed a registration statement (including a prospectus) with the U.S. Securities and Exchange Commission (the "SEC") for the offering to which this communication relates.  Investors should read the prospectus in such registration statement and other documents RBSG has filed with the SEC for more complete information about RBSG and this offering. You may get these documents for free by visiting the SEC web site at www.sec.gov.  Alternatively, copies may be obtained from NatWest Markets Securities Inc., toll free at 1-866-884-2071.

 

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

For further information, please contact:

 

Scott Forrest

Head of Debt Capital Markets and Capital Strategy

The Royal Bank of Scotland Group plc

Tel: +44 131 626 1329

 

Legal Entity Identifier:  2138005O9XJIJN4JPN90

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCLIFFAIDLIVIA

a d v e r t i s e m e n t